EA201790726A1 - Фармацевтическая композиция для лечения язвенного колита - Google Patents

Фармацевтическая композиция для лечения язвенного колита

Info

Publication number
EA201790726A1
EA201790726A1 EA201790726A EA201790726A EA201790726A1 EA 201790726 A1 EA201790726 A1 EA 201790726A1 EA 201790726 A EA201790726 A EA 201790726A EA 201790726 A EA201790726 A EA 201790726A EA 201790726 A1 EA201790726 A1 EA 201790726A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
pharmaceutical composition
colitis
ulceral
pharmaceutically acceptable
Prior art date
Application number
EA201790726A
Other languages
English (en)
Other versions
EA034956B1 (ru
Inventor
Сунсукэ Кагеяма
Ёсики Года
Тосихико Сугиура
Original Assignee
Эа Фарма Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эа Фарма Ко., Лтд. filed Critical Эа Фарма Ко., Лтд.
Publication of EA201790726A1 publication Critical patent/EA201790726A1/ru
Publication of EA034956B1 publication Critical patent/EA034956B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Предлагается фармацевтическая композиция для лечения язвенного колита, содержащая соединение, представленное формулой (1), или его фармацевтически приемлемую соль, причем указанное соединение или его фармацевтически приемлемую соль больной язвенным колитом принимает в количестве 600 мг/сут или больше.
EA201790726A 2014-09-29 2015-03-27 Способ для лечения язвенного колита EA034956B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014198681 2014-09-29
PCT/JP2015/059717 WO2016051828A1 (ja) 2014-09-29 2015-03-27 潰瘍性大腸炎の治療用医薬組成物

Publications (2)

Publication Number Publication Date
EA201790726A1 true EA201790726A1 (ru) 2017-11-30
EA034956B1 EA034956B1 (ru) 2020-04-10

Family

ID=55629887

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790726A EA034956B1 (ru) 2014-09-29 2015-03-27 Способ для лечения язвенного колита

Country Status (9)

Country Link
US (1) US10183022B2 (ru)
JP (1) JP6580053B2 (ru)
KR (1) KR102319078B1 (ru)
AU (1) AU2015326196B2 (ru)
BR (1) BR112017006272A2 (ru)
CA (1) CA2961311C (ru)
EA (1) EA034956B1 (ru)
MX (1) MX2017003780A (ru)
WO (1) WO2016051828A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973216T3 (es) * 2018-01-18 2024-06-19 Sterna Biologicals Gmbh Composición para el tratamiento de un paciente que padece colitis ulcerosa y uso de la composición como medicamento
CN112969504B (zh) 2018-10-30 2024-04-09 吉利德科学公司 用于抑制α4β7整合素的化合物
WO2020092375A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin
GB202002926D0 (en) * 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof
KR20230066169A (ko) 2021-11-05 2023-05-15 (주) 넥셀 궤양성 대장염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 궤양성 대장염 예방 또는 치료용 조성물
CN114668775B (zh) * 2022-02-28 2023-12-19 中国药科大学 纤维素衍生物在制备治疗溃疡性结肠炎药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1288205T1 (sl) 2000-08-18 2011-05-31 Ajinomoto Kk Novi derivati fenilalanina
CN101386600B (zh) 2003-02-20 2011-07-06 味之素株式会社 具有喹唑二酮骨架的苯丙氨酸衍生物的制造方法及制造中间体
CN100563658C (zh) 2003-11-14 2009-12-02 味之素株式会社 苯丙氨酸衍生物的固体分散体或固体分散体医药制剂
WO2005046697A1 (ja) 2003-11-14 2005-05-26 Ajinomoto Co., Inc. フェニルアラニン誘導体の徐放性経口投与製剤
WO2005051525A1 (en) 2003-11-25 2005-06-09 Polyvalor, Limited Partnership Permeation barrier coating or layer with modulated properties and methods of making the same
WO2005051925A1 (ja) * 2003-11-27 2005-06-09 Ajinomoto Co., Inc. フェニルアラニン誘導体の結晶及びその製造方法
EP2402326A1 (en) 2005-06-21 2012-01-04 Ajinomoto Co., Inc. Crystals of hydrochloride salts of a Phenylalanine Derivative, Production Method Thereof and Use Thereof as alpha4 integrin Inhibitors
EP2103601B1 (en) 2006-11-22 2012-03-14 Ajinomoto Co., Inc. Process for production of phenylalanine derivatives having quinazolinedione skeletons and intermediates for the production
US7987289B2 (en) 2008-06-24 2011-07-26 Microsoft Corporation Participating in cloud as totally stubby edge
EP2554169B1 (en) 2010-03-29 2019-11-20 EA Pharma Co., Ltd. Pharmaceutical preparation comprising phenylalanine derivative
EP2993173A1 (en) * 2010-03-29 2016-03-09 Ajinomoto Co., Inc. Crystals of salts of phenylalanine derivatives

Also Published As

Publication number Publication date
MX2017003780A (es) 2017-06-30
US20170196870A1 (en) 2017-07-13
AU2015326196B2 (en) 2020-05-14
JP6580053B2 (ja) 2019-09-25
EA034956B1 (ru) 2020-04-10
CA2961311C (en) 2022-12-06
WO2016051828A1 (ja) 2016-04-07
US10183022B2 (en) 2019-01-22
JPWO2016051828A1 (ja) 2017-07-27
CA2961311A1 (en) 2016-04-07
KR102319078B1 (ko) 2021-10-29
BR112017006272A2 (pt) 2018-03-13
AU2015326196A1 (en) 2017-03-23
KR20170057435A (ko) 2017-05-24

Similar Documents

Publication Publication Date Title
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
MD20170016A2 (ru) Аминопиримидиновые соединения в качестве ингибиторов JAK
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MY197626A (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MY197698A (en) Oxysterols and methods of use thereof
EA202090683A2 (ru) Способы и композиции для лечения рака
PH12016502352A1 (en) Pharmaceutical composition
MX2018004664A (es) Antagonistas de ep4.
PH12018500378A1 (en) Novel annelated phenoxyacetamides
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
TW201613578A (en) Pharmaceutical combinations
PH12018500377A1 (en) Novel annelated benzamides
NZ731607A (en) Dihydropyrimidin-2- one compounds and medical use thereof
MY186475A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201692270A1 (ru) Производные нафтиридиндиона
PH12016502568A1 (en) Novel heterocyclic compound
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
PH12016502547A1 (en) Methods for treating infections

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM